Cookson Peirce & Co. Inc. Has $11.78 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Cookson Peirce & Co. Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 17.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,258 shares of the company’s stock after acquiring an additional 2,100 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Eli Lilly and Company were worth $11,776,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Oak Ridge Investments LLC lifted its stake in shares of Eli Lilly and Company by 6.1% in the first quarter. Oak Ridge Investments LLC now owns 58,613 shares of the company’s stock worth $48,409,000 after buying an additional 3,370 shares during the last quarter. OneAscent Investment Solutions LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $203,000. Vestmark Advisory Solutions Inc. lifted its stake in shares of Eli Lilly and Company by 95.7% in the first quarter. Vestmark Advisory Solutions Inc. now owns 23,702 shares of the company’s stock worth $19,576,000 after buying an additional 11,591 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in shares of Eli Lilly and Company by 54.0% in the first quarter. Lord Abbett & CO. LLC now owns 222,962 shares of the company’s stock worth $184,147,000 after buying an additional 78,152 shares during the last quarter. Finally, Sit Investment Associates Inc. lifted its stake in shares of Eli Lilly and Company by 3.9% in the first quarter. Sit Investment Associates Inc. now owns 30,362 shares of the company’s stock worth $25,076,000 after buying an additional 1,144 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 3.3%

Shares of Eli Lilly and Company stock opened at $660.41 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company’s fifty day moving average price is $767.52 and its two-hundred day moving average price is $796.25. The firm has a market capitalization of $625.05 billion, a PE ratio of 43.16, a price-to-earnings-growth ratio of 0.90 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s payout ratio is currently 39.22%.

Insider Buying and Selling

In related news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $964.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.